Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov 03, 2014	Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call MONROVIA, Calif. , Nov. 3, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release third quarter	View HTML Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call 12.7 KB
Toggle SummaryOct 27, 2015	Xencor to Host Third Quarter 2015 Financial Results Webcast and Conference Call on November 3, 2015 MONROVIA, Calif. , Oct. 27, 2015 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release third quarter	View HTML Xencor to Host Third Quarter 2015 Financial Results Webcast and Conference Call on November 3, 2015 15.9 KB
Toggle SummaryOct 26, 2016	Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference Call on November 2, 2016 MONROVIA, Calif. , Oct. 26, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release third quarter	View HTML Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference Call on November 2, 2016 14 KB
Toggle SummaryOct 31, 2017	Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 MONROVIA, Calif. , Oct. 31, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release third quarter 2017	View HTML Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 30.8 KB
Toggle SummaryOct 29, 2018	Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018 MONROVIA, Calif. , Oct. 29, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will release third	View HTML PDF Version
Toggle SummaryOct 29, 2019	Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019 MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 29, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release third quarter	View HTML PDF Version
Toggle SummaryOct 29, 2020	Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020 MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 29, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after	View HTML PDF Version
Toggle SummaryNov 01, 2021	Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021 MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 1, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release third quarter 2021 financial	View HTML PDF Version
Toggle SummaryOct 31, 2022	Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022 MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 31, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after	View HTML PDF Version
Toggle SummaryOct 31, 2023	Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023 PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after	View HTML PDF Version

Tools

Press Releases